Clostridium Difficile News and Research

RSS
Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
LiftSeat to distribute Hygie Hygienic Cover Systems in the U.S.

LiftSeat to distribute Hygie Hygienic Cover Systems in the U.S.

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

CDIs are becoming significant issue in healthcare institutions: Study

CDIs are becoming significant issue in healthcare institutions: Study

Kettering Health Network licenses DIATHERIX Laboratories' TEM-PCR testing process

Kettering Health Network licenses DIATHERIX Laboratories' TEM-PCR testing process

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

ViroPharma reports 76% growth in fourth-quarter net product sales

ViroPharma reports 76% growth in fourth-quarter net product sales

Excelimmune receives $1M investment as part of open Series-B financing round

Excelimmune receives $1M investment as part of open Series-B financing round

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients

Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

Staying in a multi-bed hospital room increases the risk of acquiring serious infectious diseases

Staying in a multi-bed hospital room increases the risk of acquiring serious infectious diseases

Plans moving forward for Medizone International's hospital sterilization system, AsepticSure

Plans moving forward for Medizone International's hospital sterilization system, AsepticSure

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Cubist Pharmaceuticals acquires Calixa Therapeutics

Cubist Pharmaceuticals acquires Calixa Therapeutics

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Nanotherapeutics acquires Ramoplanin clinical program from Oscient Pharmaceuticals

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

Optiquant BKV Quantification Panel for MSSA DNA testing procedures

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Trial date set for patent litigation in the U.S. District Court for the District of Delaware

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.